English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Activation of peroxisome proliferator-activated receptors (PPARs)-gamma by thiazolidinediones (pioglitazone, rosiglitazone) and dual-acting PPARalpha/gamma agonists (pargluva, ragaglitazar) is a widely used pharmacological principle to treat insulin resistance and type 2 diabetes. Clinically, however, fluid retention and edema are worrying side effects with these drugs.

the journal of clinical endocrinology and metabolism/journal of clinical endocrinology and metabolism

The Pro12Ala Variant of the<i>PPARG</i>Gene Is a Risk Factor for Peroxisome Proliferator-Activated Receptor-γ/α Agonist-Induced Edema in Type 2 Diabetic Patients

The Pro12Ala Variant of thePPARGGene Is a Risk Factor for Peroxisome Proliferator-Activated Receptor-γ/α Agonist-Induced Edema in Type 2 Diabetic Patients